ArticleExperimental hematology & oncology2026
Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study.
Article in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03620955 (Risk-stratified Therapy Based on Molecular and Cytogenetic Aberration and Treatment Response in Acute Myeloid Leukemia), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risk-stratified Therapy Based on Molecular and Cytogenetic Aberration and Treatment Response in Acute Myeloid Leukemia
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetrospective studies suggested that autologous stem cell transplantation (auto-SCT) might achieve comparable or even better outcomes compared with allogeneic SCT for patients with genetic intermediate-risk acute myeloid leukemia (IR-AML) and no detectable measurable residual disease (MRD-). However, prospective studies are lacking comparing auto-SCT and matched sibling donor SCT (MSD-SCT). PATIENT AND
methodsWe initiated a biological assignment comparative study at fourteen institutions in China. Patients with newly diagnosed de novo IR-AML and MRD- within 3 cycles of intensive chemotherapy were eligible for the study if they were 14 to 60 years old and received auto-SCT or MSD-SCT. Patients were assigned to auto-SCT or MSD-SCT based on donor availability. The primary endpoint was the 3-year disease-free survival (DFS). The trial was registered with Clinicaltrials.gov, NCT03620955 and completed.
resultsBetween November 15, 2018, and March 31, 2022, 708 patients were screened and 518 eligible for analysis, including 259 in the auto-SCT and 259 in the MSD-SCT groups. With a median follow-up time of 55.2 (IQR 47.4-65.2) months, the 3-year DFS was 82.2% (95% CI 77.0-86.4) and 85.7% (95% CI 80.8-89.4) in auto-SCT and MSD-SCT respectively (HR, 1.24 [95% CI, 0.81-1.91]; p=.32). The treatment-adjusted difference was 3.2% (95% CI, - 3.1 to 9.4; p<.001). Because the upper bound of the 95% CI (9.4) did not exceed 10%, noninferiority was shown. The 3-year overall survival (OS) was 90.7% (95% CI 86.5-93.7) and 87.6% (95% CI 83.0-91.1) respectively (HR, 0.78 [95% CI, 0.47-1.30]; p=.34). In subgroup analyses, auto-SCT achieved similar DFS and OS to MSD-SCT among patients who reached MRD- in the first 2 cycles of chemotherapy, while auto-SCT had inferior DFS but similar OS for patients who achieved MRD- after 3 cycles.
conclusionsAuto-SCT achieved non-inferior DFS and similar OS compared with MSD-SCT, suggesting that auto-SCT is a viable and preferable first-line choice for IR-AML patients achieving MRD- within 3 cycles of chemotherapy, particularly those who reached MRD- in the first 2 cycles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.